A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
Clinical trial NCT07031700 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07031700
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-01
- Primary completion
- 2027-06-30
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.